CUMBERLAND, R.I.--(BUSINESS WIRE)-- Neurotech, a biotechnology company developing transformational, sight-saving therapeutics for the treatment of chronic eye diseases, announced today that Thomas Aaberg, Jr., M.D. has been appointed to the position of Chief Medical Officer (CMO). Dr. Aaberg’s responsibilities will include the execution of clinical studies, patient safety, and the management of Medical Affairs; supporting the required regulatory submissions; and supporting the Company’s development and commercial objectives. Dr. Aaberg replaces Dr. John Pollack who recently stepped down as Neurotech’s CMO.

“We are extremely pleased that Tom will be joining the Neurotech team. Tom has outstanding credentials, and he will significantly help us position our delivery platform and clinical programs for success and advance our novel treatments to the market,” said Jim Mazzo, Neurotech’s Executive Chairman.

Dr. Aaberg is board certified in ophthalmology and has extensive training in retinal diseases and ocular tumors. He has been an investigator in twenty clinical trials, authored over thirty peer-reviewed articles, wrote seven textbook chapters, and brings over thirty years of clinical ophthalmology experience to Neurotech. Dr. Aaberg practices at Retina Specialists of Michigan and is an active member in the American Academy of Ophthalmology, the American Society of Retinal Specialists, president of the Michigan Society of Eye Physicians, The Retina Society, and the American Association of Ophthalmic Oncologist and Pathologists.

“Tom’s experience as an accomplished Retinal Specialist along with his educational background as an engineer makes him a great match for the Company. We are entering the final stages of clinical development and preparing for commercial approval, and Tom’s expertise will be invaluable to us,” said Rich Small, Neurotech’s Chief Executive Officer. “I would also like to thank Dr. Pollack for the contributions that he made as our CMO this past year.”

“I am incredibly excited to be joining Neurotech at such an important time in the Company’s development. I am looking forward to working with the Neurotech team to complete the clinical program for the first encapsulated cell technology product to treat MacTel, a progressive retinal disease for which no treatment option currently exists to offer patients,” said Dr. Aaberg.

About MacTel

Macular telangiectasia type 2 (MacTel) is a disease of the retina, the light-sensing tissue at the back of the eye. MacTel affects a well-defined area of the retina, which is referred to as the “MacTel zone.” MacTel typically affects both eyes and leads to a gradual deterioration of central vision, which becomes noticeable to people around 50-60 years of age.

About Neurotech Pharmaceuticals, Inc.

Neurotech Pharmaceuticals, Inc. is a biotechnology company developing transformational, sight-saving therapeutics for the treatment of chronic eye diseases. Its patented core technology platform, Encapsulated Cell Technology (ECT), is a genetically engineered implant that enables continuous delivery of protein drugs directly into the vitreous humor of the eye over an extended period. Neurotech is clinically studying its lead product candidate, NT-501, in a Phase 3 program to treat the orphan disease Macular Telangiectasia (MacTel) and in a Phase 2 study to treat Glaucoma. To learn more, visit www.neurotechusa.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005378/en/